AbbVie settles one of its final Humira biosimilar suits for another mid-2023 delayed entry

AbbVie’s blockbuster rheumatoid arthritis drug Humira will see even more competition next year, as AbbVie and biosimilar developer Alvotech settled a court dispute over when the company’s adalimumab biosimilar can launch, even as the drug has yet to be approved by the FDA.

The settlement fully resolves all pending legal...

Click to view original post